Interferon Not Included: Say Goodbye to Hepatitis C
Newest Hepatitis C Drug Without Interferon Achieves 93 Percent Cure Rate
Written by David Heitz
Another pharmaceutical company appears headed to market with a drug that cures hepatitis C genotype 1, without interferon and ribavirin, in just 12 weeks.
Research published today in The Journal of the American Medical Association (JAMA) showed a combination of Bristol-Myers Squibb drugs daclatasvir, asunaprevir, and beclabuvir cured hepatitis C in 93 percent of 112 study participants with cirrhosis who had not previously been treated.
Continue reading this entire article: